Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 321 KB, PDF-dokument

  • Nadja Højgaard Pedersen
  • Jennifer Astrup Sørensen
  • Misbah Noshela Ghazanfar
  • Ditte Georgina Zhang
  • Christian Vestergaard
  • Thomsen, Simon Francis

Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and these are also being investigated as potential biomarkers in the diagnosis and management of the disease. As of now the only assessment tools available for treatment response are patient reported outcomes (PROs). Although these tools are both validated and widely used, they leave a desire for more objective measurements. A biomarker is a broad subcategory of observations that can be used as an accurate, reproducible, and objective indicator of clinically relevant outcomes. This could be normal biological or pathogenic processes, or a response to an intervention or exposure, e.g., treatment response. Herein we provide an overview of biomarkers for CU, with a focus on prognostic biomarkers for treatment response to omalizumab, thereby potentially aiding physicians in personalizing treatments.

TidsskriftInternational Journal of Molecular Sciences
Udgave nummer14
Sider (fra-til)1.14
StatusUdgivet - 2023

Bibliografisk note

Publisher Copyright:
© 2023 by the authors.

ID: 362061137